final program.qxd - Parallels Plesk Panel

the current focus of research is to evaluate more agressive therapeutic strategies with a
view to enhancing the response to retreatment. These studies will provide direction as to
whether the use of higher interferon doses, a longer duration of treatment, or a
combination of both increased dose and treatment duration, can enhance the response
rates currently seen. Finally, in the next 1-2 years, a clearer picture will begin to emerge
to determine the role of pegylated interferon maintenance therapy in the prevention of
cirrhosis and its associated complications (12,14, 37), and new data will be available with
the new antiviral agents.
.
References
1) Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis
C virus infection. N Engl J Med 2002;347: 975-82.
2) Hadziyannis SJ, Sette H, Jr., Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy
in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140: 346-55.
3) Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared
with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358: 958-65.
4) Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients
with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004;127: 1724-32
5) Zeuzem S, Pawlotsky J-M, Lukasiewicz E, von Wagner M, Goulis I, Lurie Y, et al. International, multicenter, randomized, controlled
study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 2005;43: 250-7.
6) McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained
response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123: 1061-9.
7) Reddy KR, Hadziyannis SJ, Diago M, Marcellin P, Lopez-Talavera JC, Wright TL. The influence of cumulative peginterferon alfa 2a
and ribavirin exposure on sustained virological response rates in patients with genotype 1 chronic hepatitis C [abstract]. J Hepatol
2005;42: 217.
8) Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds
less well? Ann Intern Med 2004;140: 370-81.
9) Chousterman M, Auray-Cartier V, Hagege H, et al. Efficacy of pegylated interferon alpha-2b in combination with ribavirin in patients
with chronic hepatitis C non-responders to a previous treatment [abstract]. J Hepatol 2003;38: 133.
10) Diago M, Romero-Gomez M, Crespo J, et al. Peginterferon alfa-2a (Pegasys) and ribavirin (Copegus) in patients infected with HCV
genotype 1 who failed to respond to interferon and ribavirin: final results of the Spanish high dose induction pilot trial [abstract].
Hepatology 2004;40: 389A.
11) Portal I, Botta-Fridlund D, Bourliere M, et al. Treatment with pegylated interferon alfa 2b in relapsers to standard interferon plus ribivirin
in chronic hepatitis C: efficacy and safety results from a randomized multicentric French study [abstract]. Hepatology 2003;38:
311A.
12) Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon alfa-2a and ribavirin in
patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004;126: 1015-23; discussion 947.
13) Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, et al. Evolution of the HALT-C Trial: pegylated interferon
as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004;25: 472-92.
14) Poynard T, Schiff E, Terg R, Goncales F, Diago M, Reichen J, et al. Sustained virological response in the EPIC 3 trial: Week twelve
virology predicts SVR in previous interferon/ribavirin failure receiving Peg-Intron/Rebetol (PR) weight based dosing (WBD) [abstract].
J Hepatol 2005;42: 40-1
15) Gitlin N, Muther K. Sustained viral response (SVR) with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis c (CHC)
who were non responders (NR) to peginterferon alfa-2b and ribavirin. Hepatology 2004;40 (suppl 1): 343A. Abstract 413
16) Herrine SK, Brown RS, Jr., Bernstein DE, Ondovik MS, Lentz E, Te H. Peginterferon alpha-2a combination therapies in chronic
hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot
study of efficacy and safety. Dig Dis Sci 2005;50: 719-26
17) Younossi ZM, McCullough AC, Barnes DS, Post A, Ong JP, O'Shea R, et al. Pegylated interferon alpha-2b, ribavirin and amantadine
for chronic hepatitis C. Dig Dis Sci 2005;50: 970-5.
18) Mangia A, Ricci GL, Persico M, Minerva N, Carretta V, Bacca D, et al. A randomized controlled trial of pegylated interferon alpha-
2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naive patients with
chronic hepatitis C. J Viral Hepat 2005;12: 292-9
19) Maynard M, Si Ahmed SN, Bailly F, et al. Retreatment of IFN/ribavirin non responder hepatitis C patients: benefit of Peginterferon/ribavirin/amantadine
[abstract]. Hepatology 2004;40: 398A.
20) Oguz D, Cicek B, Filik L, Odemis B, Kilic M, Altintas E, et al. Effect of interferon and ribavirin combined with amantadine in interferon
and ribavirin non-responder patients with chronic hepatitis C (genotype 1). World J Gastroenterol 2005;11: 580-3.
21) Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin
on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122: 1303-13.
22) Deltenre P, Henrion J, Canva V, Dharancy S, Texier F, Louvet A, et al. Evaluation of amantadine in chronic hepatitis C: a meta-analysis.
J Hepatol 2004;41: 462-73.
23) Leevy CB, Blatt L, Chalmers C. Interim results of a pilot study of the combination of type 1 (IFN alfacon) and type 2 (IFN gamma
1B) interferons in chronic hepatitis C patients who have failed to respond to PEG-interferon alfa2a plus ribavirin [abstract]. Hepatology
2004;40: 394A.
24) Poo JL, Sanchez Tapias JM, Kershenobich D, et al. A pilot trial of thymalfasin (thymosin alpha-1) in combination with peginterferon
alfa-2A and ribavirin in HCV non responders: 48 week results [abstract]. Hepatology 2004;40: 336A.
25) Bocher WO, Schuchmann M, Link R, et al. Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of
previous interferon alpha therapy. Liver Int 2006; 26: 319-325.
ABSTRACTS
“ Focusing FIRST on PEOPLE “ 77 w w w . i s h e i d . c o m